Logo image of ALIKO.PA

IKONISYS SA (ALIKO.PA) Stock Fundamental Analysis

EPA:ALIKO - Euronext Paris - Matif - FR00140048X2 - Common Stock - Currency: EUR

1.56  +0.02 (+1.3%)

Fundamental Rating

1

Taking everything into account, ALIKO scores 1 out of 10 in our fundamental rating. ALIKO was compared to 53 industry peers in the Health Care Equipment & Supplies industry. ALIKO has a bad profitability rating. Also its financial health evaluation is rather negative. ALIKO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALIKO has reported negative net income.
ALIKO had a negative operating cash flow in the past year.
In the past 5 years ALIKO always reported negative net income.
ALIKO had a negative operating cash flow in each of the past 5 years.
ALIKO.PA Yearly Net Income VS EBIT VS OCF VS FCFALIKO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 -500K -1M -1.5M -2M

1.2 Ratios

The Return On Assets of ALIKO (-10.87%) is worse than 60.38% of its industry peers.
ALIKO has a Return On Equity of -14.41%. This is comparable to the rest of the industry: ALIKO outperforms 41.51% of its industry peers.
Industry RankSector Rank
ROA -10.87%
ROE -14.41%
ROIC N/A
ROA(3y)-8.23%
ROA(5y)-11.93%
ROE(3y)-10.37%
ROE(5y)-15.89%
ROIC(3y)N/A
ROIC(5y)N/A
ALIKO.PA Yearly ROA, ROE, ROICALIKO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -10 -20

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALIKO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALIKO.PA Yearly Profit, Operating, Gross MarginsALIKO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

1

2. Health

2.1 Basic Checks

ALIKO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALIKO has more shares outstanding
The debt/assets ratio for ALIKO is higher compared to a year ago.
ALIKO.PA Yearly Shares OutstandingALIKO.PA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M 8M
ALIKO.PA Yearly Total Debt VS Total AssetsALIKO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

ALIKO has an Altman-Z score of 1.67. This is a bad value and indicates that ALIKO is not financially healthy and even has some risk of bankruptcy.
ALIKO has a Altman-Z score (1.67) which is in line with its industry peers.
ALIKO has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ALIKO (0.10) is better than 83.02% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z 1.67
ROIC/WACCN/A
WACC7.73%
ALIKO.PA Yearly LT Debt VS Equity VS FCFALIKO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M 10M 15M 20M

2.3 Liquidity

ALIKO has a Current Ratio of 0.20. This is a bad value and indicates that ALIKO is not financially healthy enough and could expect problems in meeting its short term obligations.
ALIKO's Current ratio of 0.20 is on the low side compared to the rest of the industry. ALIKO is outperformed by 90.57% of its industry peers.
ALIKO has a Quick Ratio of 0.20. This is a bad value and indicates that ALIKO is not financially healthy enough and could expect problems in meeting its short term obligations.
ALIKO has a worse Quick ratio (0.06) than 90.57% of its industry peers.
Industry RankSector Rank
Current Ratio 0.2
Quick Ratio 0.06
ALIKO.PA Yearly Current Assets VS Current LiabilitesALIKO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 1M 2M 3M

More info and screens

5

3. Growth

3.1 Past

ALIKO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.92%.
ALIKO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.59%.
ALIKO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.20% yearly.
EPS 1Y (TTM)-6.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.48%
Revenue 1Y (TTM)14.59%
Revenue growth 3Y5.2%
Revenue growth 5YN/A
Sales Q2Q%130.8%

3.2 Future

ALIKO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.29% yearly.
ALIKO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 89.44% yearly.
EPS Next Y-16.25%
EPS Next 2Y10.68%
EPS Next 3Y16.04%
EPS Next 5Y29.29%
Revenue Next Year0%
Revenue Next 2Y73.21%
Revenue Next 3Y91.29%
Revenue Next 5Y89.44%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALIKO.PA Yearly Revenue VS EstimatesALIKO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10M 20M 30M
ALIKO.PA Yearly EPS VS EstimatesALIKO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.1 -0.1 -0.2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALIKO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALIKO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALIKO.PA Price Earnings VS Forward Price EarningsALIKO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALIKO.PA Per share dataALIKO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALIKO's earnings are expected to grow with 16.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.68%
EPS Next 3Y16.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALIKO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IKONISYS SA

EPA:ALIKO (5/8/2025, 7:00:00 PM)

1.56

+0.02 (+1.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners54.05%
Inst Owner ChangeN/A
Ins Owners2.61%
Ins Owner ChangeN/A
Market Cap21.51M
Analysts86.67
Price Target4.18 (167.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 47.95
P/FCF N/A
P/OCF N/A
P/B 1.37
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.03
BVpS1.14
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.87%
ROE -14.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-8.23%
ROA(5y)-11.93%
ROE(3y)-10.37%
ROE(5y)-15.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.2
Quick Ratio 0.06
Altman-Z 1.67
F-Score2
WACC7.73%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.48%
EPS Next Y-16.25%
EPS Next 2Y10.68%
EPS Next 3Y16.04%
EPS Next 5Y29.29%
Revenue 1Y (TTM)14.59%
Revenue growth 3Y5.2%
Revenue growth 5YN/A
Sales Q2Q%130.8%
Revenue Next Year0%
Revenue Next 2Y73.21%
Revenue Next 3Y91.29%
Revenue Next 5Y89.44%
EBIT growth 1Y9.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.44%
EBIT Next 3Y25.99%
EBIT Next 5Y33.05%
FCF growth 1Y20.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.63%
OCF growth 3YN/A
OCF growth 5YN/A